694
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Hepatocellular Carcinoma Risk Scores: Ready to Use in 2015?

, , &
Pages 1-4 | Published online: 12 Jan 2015

References

  • Chen CJ , HsuWL, YangHIet al. Epidemiology of virus infection and human cancer. Recent Results Cancer Res.193, 11–32 (2014).
  • Chen CJ , YuMW, LiawYF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J. Gastroenterol. Hepatol.12(9–10), S294–S308 (1997).
  • Huang YT , JenCL, YangHIet al. Lifetime risk and gender difference of hepatocellular carcinoma among patients affected with chronic hepatitis B and C. J. Clin. Oncol.29, 3643–3650 (2011).
  • Chen CJ , ChenDS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology36(5), 1046–1049 (2002).
  • Chen CJ , YangHI. Natural history of chronic hepatitis B REVEALed. J. Gastroenterol. Hepatol.26(4), 628–638 (2011).
  • Lee MH , YangHI, YuanY, L'italienG, ChenCJ. Epidemiology and natural history of hepatitis C virus infection. World J. Gastroenterol.20(28), 9270–9280 (2014).
  • Yang HI , LuSN, LiawYFet al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med.347(3), 168–174 (2002).
  • Chen CJ , YangHI, SuJet al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
  • Yang HI , YehSH, ChenPJet al. Association between Hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst.100, 1134–1143 (2008).
  • Chen CJ , YangHI, IloejeUH, GroupR-HS. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology49(Suppl. 5), S72–S84 (2009).
  • Lee MH , YangHI, LuSNet al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol.28(30), 4587–4593 (2010).
  • Lee MH , YangHI, LuSNet al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int. J. Cancer135(5), 1119–1126 (2014).
  • Yang HI , LeeMH, LiuJ, ChenCJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J. Gastroenterol.20(20), 6244–6251 (2014).
  • Lee MH , LuSN, YuanYet al. Development and validation of a clinical scoring system for predicting risk of hepatocellular carcinoma in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS ONE9, e94760 (2014).
  • Yuen MF , TanakaY, FongDYet al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol.50(1), 80–88 (2009).
  • Abu Dayyeh BK , YangM, FuchsBCet al. A Functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology141(1), 141–149 (2011).
  • Lok AS , SeeffLB, MorganTRet al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease. Gastroenterology136(1), 138–148 (2009).
  • Yu ML , LinSM, LeeCMet al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology44(5), 1086–1097 (2006).
  • Wong GL , ChanHL, ChanHYet al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology144(5), 933–944 (2013).
  • Wong VW , ChanSL, MoFet al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol.28(10), 1660–1665 (2010).
  • Yang HI , ShermanM, SuJet al. Nomograms for risk of heptocellular carcinoma in patients with chronic heaptitis B virus infection. J. Clin. Oncol.28, 2437–2444 (2010).
  • Yang HI , YuenMF, ChanHLet al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol.12, 568–574 (2011).
  • Lee MH , YangHI, LiuJet al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology58(2), 546–554 (2013).
  • Fontana RJ , DienstagJL, BonkovskyHLet al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut59(10), 1401–1409 (2010).
  • Ghany MG , LokASF, EverhartJEet al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology138(1), 136–146 (2010).
  • Imbert-Bismut F , RatziuV, PieroniLet al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet357(9262), 1069–1075 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.